CANC – Tema Oncology ETF
Tema Oncology ETF (CANC) is a Health ETF, issued by Tema Global Limited, $143M in assets, 0.75% expense ratio.
Returns as of Oct 23, 2026: 1 week +4.1%, 1 year +47.0%.
Oncology companies: Invests 80% in publicly listed firms deriving at least 50% of revenues from oncology.
Top holdings
- RVMD – Revolution Medicines Inc, 7.2%
- NOVN – Novartis AG, 4.8%
- LLY – Eli Lilly and Company, 4.5%
- BBIO – BridgeBio Pharma Inc, 4.4%
- AZN – AstraZeneca PLC, 4.2%
- RHHBY – Roche Holding Ltd ADR, 4.2%
- MRK – Merck & Company Inc, 3.9%
- UMRX – Cogent Biosciences Inc, 3.6%
- GMAB – Genmab AS, 3.5%
- BMY – Bristol-Myers Squibb Company, 3.4%
- NUVL – Nuvalent Inc, 3.2%
- EXEL – Exelixis Inc, 3.0%
- AMGN – Amgen Inc, 2.8%
- JNJ – Johnson & Johnson, 2.8%
- IMNM – Immunome Inc, 2.7%
- CELC – Celcuity LLC, 2.5%
- ACLX – Arcellx Inc, 2.4%
- ABBV – AbbVie Inc, 2.3%
- BGNE – BeiGene Ltd, 2.3%
- IDYA – Ideaya Biosciences Inc, 2.1%
- LEGN – Legend Biotech Corp, 1.8%
- SNDX – Syndax Pharmaceuticals Inc, 1.7%
- CGON – CG Oncology, Inc. Common stock, 1.7%
- ZA8 – ZYMEWORKS DL-00001, 1.5%
- HALO – Halozyme Therapeutics Inc, 1.5%